Search Results - "Streicher, Howard"

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study by Morris, Van K, MD, Salem, Mohamed E, MD, Nimeiri, Halla, MD, Iqbal, Syma, MD, Singh, Preet, MD, Ciombor, Kristen, MD, Polite, Blase, MD, Deming, Dustin, MD, Chan, Emily, MD, Wade, James L, MD, Xiao, Lianchun, MS, Bekaii-Saab, Tanios, Prof, Vence, Luis, PhD, Blando, Jorge, DVM, Mahvash, Armeen, MD, Foo, Wai Chin, MD, Ohaji, Chimela, MD, Pasia, Manolo, BSN, Bland, Gail, BS, Ohinata, Aki, PAC, Rogers, Jane, PharmD, Mehdizadeh, Amir, MA, Banks, Kimberly, MS, Lanman, Richard, MD, Wolff, Robert A, Prof, Streicher, Howard, MD, Allison, James, Prof, Sharma, Padmanee, Prof, Eng, Cathy, Prof

“…Summary Background Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papillomavirus (HPV). No consensus…”
Get full text

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 by Atkins, Michael B, Lee, Sandra J, Chmielowski, Bartosz, Tarhini, Ahmad A, Cohen, Gary I, Truong, Thach-Giao, Moon, Helen H, Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J, Curti, Brendan D, Urba, Walter J, Brell, Joanna M, Funchain, Pauline, Kendra, Kari L, Ikeguchi, Alexandra P, Jaslowski, Anthony, Bane, Charles L, Taylor, Mark A, Bajaj, Madhuri, Conry, Robert M, Ellis, Robert J, Logan, Theodore F, Laudi, Noel, Sosman, Jeffrey A, Crockett, David G, Pecora, Andrew L, Okazaki, Ian J, Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X, Streicher, Howard Z, Wolchok, Jedd D, Ribas, Antoni, Kirkwood, John M

“…Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in…”
Get full text

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study by Azad, Nilofer S, Gray, Robert J, Overman, Michael J, Schoenfeld, Jonathan D, Mitchell, Edith P, Zwiebel, James A, Sharon, Elad, Streicher, Howard, Li, Shuli, McShane, Lisa M, Rubinstein, Larry, Patton, David R, Williams, P Mickey, Coffey, Brent, Hamilton, Stanley R, Bahary, Nathan, Suga, J Marie, Hatoum, Hassan, Abrams, Jeffrey S, Conley, Barbara A, Arteaga, Carlos L, Harris, Lyndsay, O'Dwyer, Peter J, Chen, Alice P, Flaherty, Keith T

“…The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest national precision oncology study to date (> 1,100 sites) of…”
Get full text

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin, Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Anderson, Adrienne, Boardman, Alexander P., Weber, Augustine, Avigan, David, Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey, Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Ritz, Jerome, Streicher, Howard, Ball, Edward D., Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell…”
Get full text

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation by Masucci, Giuseppe V., Cesano, Alessandra, Hawtin, Rachael, Janetzki, Sylvia, Zhang, Jenny, Kirsch, Ilan, Dobbin, Kevin K., Alvarez, John, Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Butterfield, Lisa H., Thurin, Magdalena

“…Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using…”
Get full text

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) by Wagner, Michael J, Othus, Megan, Patel, Sandip P, Ryan, Chris, Sangal, Ashish, Powers, Benjamin, Budd, G Thomas, Victor, Adrienne I, Hsueh, Chung-Tsen, Chugh, Rashmi, Nair, Suresh, Leu, Kirsten M, Agulnik, Mark, Sharon, Elad, Mayerson, Edward, Plets, Melissa, Blanke, Charles, Streicher, Howard, Chae, Young Kwang, Kurzrock, Razelle

“…PurposeAngiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in…”
Get full text

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation by Penter, Livius, Zhang, Yi, Savell, Alexandra, Huang, Teddy, Cieri, Nicoletta, Thrash, Emily M., Kim-Schulze, Seunghee, Jhaveri, Aashna, Fu, Jingxin, Ranasinghe, Srinika, Li, Shuqiang, Zhang, Wandi, Hathaway, Emma S., Nazzaro, Matthew, Kim, Haesook T., Chen, Helen, Thurin, Magdalena, Rodig, Scott J., Severgnini, Mariano, Cibulskis, Carrie, Gabriel, Stacey, Livak, Kenneth J., Cutler, Corey, Antin, Joseph H., Nikiforow, Sarah, Koreth, John, Ho, Vincent T., Armand, Philippe, Ritz, Jerome, Streicher, Howard, Neuberg, Donna, Hodi, F. Stephen, Gnjatic, Sacha, Soiffer, Robert J., Liu, X. Shirley, Davids, Matthew S., Bachireddy, Pavan, Wu, Catherine J.

“…Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune…”
Get full text

Melanoma: a model for testing new agents in combination therapies by Ascierto, Paolo A, Streicher, Howard Z, Sznol, Mario

“…Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials…”
Get full text

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations by Dobbin, Kevin K., Cesano, Alessandra, Alvarez, John, Hawtin, Rachael, Janetzki, Sylvia, Kirsch, Ilan, Masucci, Giuseppe V., Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Zhang, Jenny, Butterfield, Lisa H., Thurin, Magdalena

“…There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a…”
Get full text

Biology of advanced uveal melanoma and next steps for clinical therapeutics by Luke, Jason J., Triozzi, Pierre L., McKenna, Kyle C., Van Meir, Erwin G., Gershenwald, Jeffrey E., Bastian, Boris C., Gutkind, J. Silvio, Bowcock, Anne M., Streicher, Howard Z., Patel, Poulam M., Sato, Takami, Sossman, Jeffery A., Sznol, Mario, Welch, Jack, Thurin, Magdalena, Selig, Sara, Flaherty, Keith T., Carvajal, Richard D.

“…Summary Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to…”
Get full text

Ocular adverse events in PD-1 and PD-L1 inhibitors by Young, LeAnne, Finnigan, Shanda, Streicher, Howard, Chen, Helen X, Murray, James, Sen, H Nida, Sharon, Elad

“…BackgroundProgrammed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors can cause unique immune-related adverse effects due to non-specific…”
Get full text

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males by Saad, Mariam, Lee, Sandra J, Tan, Aik Choon, El Naqa, Issam M, Hodi, F Stephen, Butterfield, Lisa H, LaFramboise, William A, Storkus, Walter, Karunamurthy, Arivarasan D, Conejo-Garcia, Jose, Hwu, Patrick, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M, Tarhini, Ahmad A

“…We hypothesized that a gender difference in clinical response may exist to adjuvant CTLA4 blockade with ipilimumab versus high-dose IFNα (HDI). We investigated…”
Get full text

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort by Patel, Sandip P, Othus, Megan, Chae, Young Kwang, Huynh, Tridu, Tan, Benjamin, Kuzel, Timothy, McLeod, Christine, Lopez, Gabby, Chen, Helen X, Sharon, Elad, Streicher, Howard, Ryan, Christopher W, Blanke, Charles, Kurzrock, Razelle

“…ObjectivesMultiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical…”
Get full text

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors by Rahma, Osama E, Tyan, Kevin, Giobbie-Hurder, Anita, Brohl, Andrew S, Bedard, Philippe L, Renouf, Daniel J, Sharon, Elad, Streicher, Howard, Hathaway, Emma, Cunningham, Rachel, Manos, Michael, Severgnini, Mariano, Rodig, Scott, Stephen Hodi, F

“…BackgroundThe combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor…”
Get full text

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses by Seligson, Nathan D, Chen, James L, Goodrich, Austin C, Van Tine, Brian A, Campbell, Jordan D, Richards, Allison L, Antonescu, Cristina R, Liebner, David A, Milhem, Mohammed M, Streicher, Howard, Tap, William D, Schwartz, Gary K, George, Suzanne, D'Angelo, Sandra P

“…In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N)…”
Get full text

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors by Chae, Young Kwang, Othus, Megan, Patel, Sandip, Powers, Benjamin, Hsueh, Chung-Tsen, Govindarajan, Rangaswamy, Bucur, Silvana, Kim, Hye Sung, Chung, Liam Il-Young, McLeod, Christine, Chen, Helen X, Sharon, Elad, Streicher, Howard, Ryan, Christopher W, Blanke, Charles, Kurzrock, Razelle

“…Dual inhibition using anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors has proven effective in many…”
Get full text

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III by Einstein, Mark H, Kadish, Anna S, Burk, Robert D, Kim, Mimi Y, Wadler, Scott, Streicher, Howard, Goldberg, Gary L, Runowicz, Carolyn D

“…Abstract Objectives. SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat…”
Get full text

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT) by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin L., Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Avigan, David E., Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey S., Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Streicher, Howard, Ball, Edward D, Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Patients (pts) with relapsed hematologic malignancies (HM) after alloHCT are a unique population, given the potential to harness a dormant graft-vs.-tumor…”
Get full text

45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma by Tarhini, Ahmad A, Obermayer, Alyssa, Lee, Sandra J, LaFramboise, William A, Stephen Hodi, F, Karunamurthy, Arivarasan D, Hwu, Patrick, Chen, Dung-tsa, Naqa, Issam El, Streicher, Howard, Storkus, Walter J, Butterfield, Lisa H, Kirkwood, John M, Shaw, Timothy I

“…BackgroundIpilimumab improved outcomes for high-risk melanoma patients compared to interferon-α2b in phase III adjuvant trial E1609 (NCT01274338) to which…”
Get full text

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors by Tyan, Kevin, Rahma, Osama, Giobbie-Hurder, Anita, Brohl, Andrew, Bedard, Philippe, Renouf, Daniel, Sharon, Elad, Streicher, Howard, Hathaway, Emma, Cunningham, Rachel, Manos, Michael, Severgnini, Mariano, Rodig, Scott, Stephen Hodi, F

“…BackgroundAngiogenic factors play a role in regulating immune suppression in the tumor microenvironment and driving resistance to immune checkpoint inhibitor…”
Get full text